Table 2.
Antiviral treatment in patients with indolent B-cell lymphoma associated with HCV infection.
| Year | N° pts | Diagnosis | Genotypes | Cryoglobulinemia | Antiviral treatment | Virologic response | NHL response | |
|---|---|---|---|---|---|---|---|---|
| Bauduer [63] | 1996 | 1 | MZL of MALT (oral cavity) | NA | — | α-IFN | 1 | 1 PR |
| Caramaschi et al. [64] | 1999 | 1 | MZL of MALT (salivary glands) | NA | — | α-IFN | NA | 1 CR |
| Moccia et al. [65] | 1999 | 3 | SMZL | NA | — | α-IFN | NA | 2 CR |
| Patriarca et al. [66] | 2001 | 1 | LPL | 2a/2c | — | α-IFN | 1 | 1 CR |
| Hermine et al. [5] | 2002 | 9 | SLVL | NA | 6 | α-IFN | 7 | 7 CR |
| Casato et al. [67] | 2002 | 1 | Leukemic MZL | NA | 1 | α-IFN | Decreased HCV-RNA | 1 CR |
| Pitini et al. [68] | 2004 | 2 | SMZL | NA | — | α-IFN | 2 | 2 CR |
| Tursi et al. [69] | 2004 | 16 | MZL of MALT (stomach) | NA | — | α-IFN-2b + RBV | 11/16 | 16 CR |
| Kelaidi et al. [70] | 2004 | 8 | SMZL (n = 4) Disseminated MZL (n = 1) Leukemic MZL (n = 1) MZL of MALT (n = 2) (1 duodenus; 1 ileus) |
3a (n = 1), 5a (n = 1) — 1b 4c/4d |
8 | α-IFN-2b + RBV | 5 SVR, 2 PR | 5 CR |
| Vallisa et al. [71] | 2005 | 13 | SMZL (n = 4) NMZL (n = 2) MZL of MALT (n = 2) FL (n = 1) LPL (n = 4) |
1b (n = 2), 2b (n = 1) 2a/2c (n = 1), 1b (n = 1) 1b (n = 2) 2a 2a/2c (n = 1), 1n (n = 1), na (n = 2) |
5 | Peg-IFN + RBV | 7 SVR, 1 PR | 7 CR, 2 PR |
| Svoboda et al. [72] | 2005 | 1 | MZL of MALT (salivary gland, liver) | 2b | — | Peg-IFN + RBV | 1 | CR |
| Saadoun et al. [17] | 2005 | 18 | SLVL | 1 (n = 7) 2 (n = 4) 3 (n = 1) 4 (n = 1) |
18 | α-IFN (+ RBV in 10) | 14 CR, 4 PR | 14 CR, 4 PR |
| Paulli et al. [21] | 2009 | 2 | Subcutaneous MZL of MALT | 2a/2c 2b |
2 | Peg-IFN + RBV | 2 CR | 1 CR, 1 PR |
| Oda et al. [73] | 2010 | 1 | B-NHL (liver) | 2a | — | Peg-IFN + RBV | SVR | CR |
| Mauro et al. [74] | 2012 | 1 | LPL | 1b | 1 | Peg-IFN + RBV (2nd line) | SVR | CR |
| Mazzaro et al. [75] | 2009 | 18 | 1 SLVL 1 FL 16 LPL |
1b (n = 11) 2a/2c (n = 7) |
13 |
α-IFN + RBV (n = 8) Peg-IFN + RBV (n = 10) |
9 SVR | 9 CR, 4 PR |
SMZL: splenic marginal zone lymphoma; NMZL: nodal marginal zone lymphoma; SLVL: splenic lymphoma with villous lymphocytes; MZL: marginal zone lymphoma; FL: follicular lymphoma; LPL: lymphoplasmacytic lymphoma; MCL: mantle cell lymphoma; SLL: small lymphocytic lymphoma; NHL: non-Hodgkin's lymphoma; NOS: not otherwise specified; IFN: interferon; RBV: ribavirin; CR: complete response; PR: partial response; SVR: sustained virologic response.